Vaxart Inc (NASDAQ: VXRT)’s stock price has dropped by -0.52 in relation to previous closing price of 0.67. Nevertheless, the company has seen a loss of -2.12% in its stock price over the last five trading days. seekingalpha.com reported 2024-06-27 that Vaxart Inc is developing oral vaccines for COVID-19, norovirus, and influenza with promising early clinical results but financial struggles. Vaxart received $453M funding from BARDA for a 10,000-patient Phase 2b trial comparing their COVID-19 oral vaccine to an mRNA vaccine. Despite a stock price spike following the news, Vaxart faced investor disappointment with a $40M offering shortly after the BARDA funding announcement.
Is It Worth Investing in Vaxart Inc (NASDAQ: VXRT) Right Now?
The 36-month beta value for VXRT is at 0.66. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VXRT is 225.46M, and currently, shorts hold a 5.49% of that float. The average trading volume for VXRT on July 25, 2024 was 4.12M shares.
VXRT’s Market Performance
The stock of Vaxart Inc (VXRT) has seen a -2.12% decrease in the past week, with a -3.06% drop in the past month, and a -5.72% fall in the past quarter. The volatility ratio for the week is 5.05%, and the volatility levels for the past 30 days are at 7.23% for VXRT. The simple moving average for the past 20 days is -0.45% for VXRT’s stock, with a -20.49% simple moving average for the past 200 days.
Analysts’ Opinion of VXRT
Many brokerage firms have already submitted their reports for VXRT stocks, with Jefferies repeating the rating for VXRT by listing it as a “Buy.” The predicted price for VXRT in the upcoming period, according to Jefferies is $12 based on the research report published on December 29, 2021 of the previous year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VXRT reach a price target of $15. The rating they have provided for VXRT stocks is “Overweight” according to the report published on November 02nd, 2021.
B. Riley Securities gave a rating of “Neutral” to VXRT, setting the target price at $9 in the report published on June 29th of the previous year.
VXRT Trading at -10.88% from the 50-Day Moving Average
After a stumble in the market that brought VXRT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.55% of loss for the given period.
Volatility was left at 7.23%, however, over the last 30 days, the volatility rate increased by 5.05%, as shares sank -1.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.44% lower at present.
During the last 5 trading sessions, VXRT fell by -2.17%, which changed the moving average for the period of 200-days by -7.12% in comparison to the 20-day moving average, which settled at $0.6718. In addition, Vaxart Inc saw 16.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VXRT starting from Watson W. Mark, who purchase 20,000 shares at the price of $0.68 back on Jun 18 ’24. After this action, Watson W. Mark now owns 78,125 shares of Vaxart Inc, valued at $13,578 using the latest closing price.
Stock Fundamentals for VXRT
Current profitability levels for the company are sitting at:
- -11.32 for the present operating margin
- 0.36 for the gross margin
The net margin for Vaxart Inc stands at -11.31. The total capital return value is set at -1.1. Equity return is now at value -112.40, with -74.81 for asset returns.
Based on Vaxart Inc (VXRT), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -9.57. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -39.48.
Currently, EBITDA for the company is -78.85 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 20.71. The receivables turnover for the company is 3.15for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.14.
Conclusion
In conclusion, Vaxart Inc (VXRT) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
